EGFR and neoplasm: These results indicate that the upregulated miR-1 might suppress the tumor immune microenvironment after developing EGFR-TKI resistance indicating miR-1 as a clinically useful marker to predict the therapeutic efficiency of immunotherapy in LADC patients with EGFR-TKI resistance [179].